STOCK TITAN

Harte-Hanks, Inc. (HHS) Financials

HHS
Trailing 12 months to June 30, 2026
Revenue $154.6M -11.6% YoY
Net Income -$5.7M n/m YoY
EPS (Diluted) -$0.76 n/m YoY
Free Cash Flow -$1.5M n/m YoY
Market Cap $29.2M as of Oct 23, 2026
Price / Sales 0.2x on $154.6M revenue, trailing 12 months to June 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026
Price / Book 1.9x on $15.3M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 23, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the HHS SEC filings page.

Harte-Hanks, Inc. (HHS) reported $154.6M in revenue over the twelve months to Jun 30, 2026, down 11.6% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI HHS FY2025

Shrinking revenue has left Harte Hanks with near-zero operating profit, recurring cash outflows, and a balance sheet that remains leveraged.

Revenue fell from $206M in FY2022 to $160M in FY2025, while operating margin compressed. That pairing points to a cost base that has not adjusted with the smaller revenue stream, rather than simply reflecting weaker sales.

Total assets declined from $123M in FY2023 to $92M in FY2025, reducing the scale supporting operations. Short-term coverage remains above one at a 1.5x current ratio, while the reported liquidity comparison equals 38.6 months of annual operating outflow; this cushions timing pressure but does not change the earnings picture.

Cash conversion is uneven rather than merely weak: FY2022 produced $28.8M of operating cash flow, whereas FY2025 was negative. With free cash flow also negative at $4.5M in FY2025, accounting results are not translating into internally generated funds. The gap matters because reported operating profitability has not been accompanied by dependable cash generation across the latest periods.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 46 / 100
Financial Health Score (4 of 6 dimensions) 46/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 4 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Harte-Hanks, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
66

Harte-Hanks, Inc. held $5.6M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $1.7M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Harte-Hanks, Inc. scores 66/100 among other emerging companies.

Dilution
68

Harte-Hanks, Inc. had 7M shares outstanding at the end of fiscal year 2025, against 7M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Harte-Hanks, Inc. scores 68/100 among other emerging companies.

R&D Intensity
n/a

Not available for Harte-Hanks, Inc., so it is left out of the overall score, which averages the 4 of 6 dimensions that can be computed.

Revenue Progress
33

Harte-Hanks, Inc. reported revenue of $159.6M in fiscal year 2025, against $185.2M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Harte-Hanks, Inc. scores 33/100 among other emerging companies.

Burn Trend
n/a

Not available for Harte-Hanks, Inc., so it is left out of the overall score, which averages the 4 of 6 dimensions that can be computed.

Balance Sheet
15

Harte-Hanks, Inc.'s cash, cash equivalents and investments came to $5.6M at the end of fiscal year 2025, against $71.3M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Harte-Hanks, Inc. scores 15/100 among other emerging companies.

Altman Z-Score Safe
14.62

Harte-Hanks, Inc. scores 14.62, well above the 2.99 safe threshold. The largest contribution to the score comes from retained earnings of $813.8M against total assets of $91.8M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
2/7

Harte-Hanks, Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) does not pass.

Earnings Quality No Cash Backing
N/A

Harte-Hanks, Inc. reported a net loss of $811K while operations used $1.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
1.56x

Harte-Hanks, Inc. earns $1.56 in operating income for every $1 of interest expense ($386K vs $248K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$38.0M
YoY-1.7%
QoQ+1.9%
5Y CAGR-5.1%
10Y CAGR-9.0%

Harte-Hanks, Inc. generated $38.0M in revenue in Q2 2026. This represents a decrease of 1.7% from the same quarter a year earlier. Against the prior quarter it is up 1.9%.

EBITDA
-$3.4M
YoY-406.5%
QoQ-1172.6%
10Y CAGRn/m

Harte-Hanks, Inc.'s EBITDA was -$3.4M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 406.5% from the same quarter a year earlier. Against the prior quarter it is down 1172.6%.

Net Income
-$5.0M
YoYn/m
QoQn/m
10Y CAGRn/m

Harte-Hanks, Inc. reported a net loss of $5.0M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.67
YoYn/m
QoQn/m

Harte-Hanks, Inc. earned -$0.67 per diluted share (EPS) in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow
-$2.1M
YoYn/m
QoQn/m

Harte-Hanks, Inc. recorded an outflow of $2.1M in free cash flow in Q2 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$5.2M
YoY+10.8%
QoQ+14.4%
5Y CAGR-15.3%
10Y CAGR-8.7%

Harte-Hanks, Inc. held $5.2M in cash as of Q2 2026; no long-term debt figure is on record for that period.

Shares Outstanding
7M
YoY+0.5%
QoQ+0.5%
5Y CAGR+1.9%

Harte-Hanks, Inc. had 7M shares outstanding in Q2 2026. This represents an increase of 0.5% from the same quarter a year earlier. Against the prior quarter it is up 0.5%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Operating Margin
-11.8%
YoY-11.9pp
QoQ-9.8pp
5Y change-14.7pp
10Y change-5.0pp

Harte-Hanks, Inc.'s operating margin was -11.8% in Q2 2026, reflecting core business profitability. This is down 11.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 9.8 percentage points.

Net Margin
-13.2%
YoY-12.3pp
QoQ-11.5pp
5Y change-34.6pp
10Y change-8.8pp

Harte-Hanks, Inc.'s net profit margin was -13.2% in Q2 2026, showing the share of revenue converted to profit. This is down 12.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 11.5 percentage points.

Return on Equity
-32.6%
YoY-31.1pp
QoQ-29.5pp

Harte-Hanks, Inc.'s quarterly ROE was -32.6% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is down 31.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 29.5 percentage points.

Gross Margin

Not reported for Q2 2026.

Capital Allocation

Capital Expenditures
$41K
YoY-81.6%
QoQ-88.2%
5Y CAGR-30.3%
10Y CAGR-31.6%

Harte-Hanks, Inc. invested $41K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 81.6% from the same quarter a year earlier. Against the prior quarter it is down 88.2%.

R&D Spending

Not reported for Q2 2026.

Share Buybacks

Not reported for Q2 2026.

HHS Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HHS quarterly income statement
MetricQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-Q
Revenue$38.0M-1.7%$37.3M-10.3%$39.9M-15.4%$39.5M-17.0%$38.6M-14.2%$41.6M-8.6%$47.1M-4.8%$47.6M+1.1%
SG&A Expenses$8.8M+58.6%$5.6M-3.5%$5.7M-0.9%$5.1M-2.1%$5.5M-5.4%$5.8M-1.6%$5.7M+24.5%$5.3M+6.9%
Operating Income-$4.5M-13305.9%-$768Kn/m-$117Kn/m$509K-73.2%$34K-97.5%-$40K-110.7%-$1.6Mn/m$1.9M-34.9%
EBITDA-$3.4M-406.5%$314K-69.3%$1.0Mn/m$1.7M-41.2%$1.1M-54.1%$1.0M-28.0%-$275Kn/m$2.9M-24.0%
Interest Expense$90K+47.5%$69K+30.2%$50K-37.5%$84K+47.4%$61K+56.4%$53K+381.8%$80Kn/m$57K+67.6%
Income Tax$120Kn/m-$370Kn/m-$2.5M-540.2%$2.6M+200.1%-$78Kn/m-$215Kn/m$570Kn/m$868K-54.6%
Net Income-$5.0Mn/m-$628Kn/m$2.2Mn/m-$2.3M-1709.9%-$335Kn/m-$392Kn/m-$2.4Mn/m$142K-77.0%
EPS (Basic)-$0.67n/m-$0.08n/m$0.30n/m-$0.31-1650.0%-$0.05n/m-$0.05n/m-$0.32n/m$0.02-77.8%
EPS (Diluted)-$0.67n/m-$0.08n/m$0.30n/m-$0.31-1650.0%-$0.05n/m-$0.05n/m-$0.32n/m$0.02-75.0%
Diluted Shares (Avg)7M+0.7%7M+0.8%N/A7M+0.2%7M+1.7%7M+1.7%N/A7M+1.1%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses.

HHS Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HHS quarterly balance sheet
MetricQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-Q
Total Assets$88.1M-7.3%$90.4M-10.1%$91.8M-9.8%$92.7M-14.3%$95.0M-13.4%$100.6M-11.3%$101.8M-17.1%$108.1M-2.4%
Current Assets$45.4M-9.3%$45.8M-14.8%$46.3M-13.6%$48.7M-9.5%$50.0M-9.2%$53.7M-7.0%$53.6M-17.8%$53.8M-13.5%
Cash & Equivalents$5.2M+10.8%$4.5M-47.9%$5.6M-43.1%$6.5M+9.5%$4.7M-57.4%$8.7M-24.1%$9.8M-46.6%$5.9M-55.3%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Accounts Receivable$27.4M-20.3%$26.1M-11.7%$27.8M-12.0%$30.2M-9.2%$34.4M+12.6%$29.6M-9.7%$31.6M-7.8%$33.3M-0.1%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Goodwill$295K0.0%$295K0.0%$295K0.0%$295K-84.7%$295K-84.7%$295K-84.7%$295K-84.7%$1.9M-20.6%
Total Liabilities$72.7M-0.1%$70.3M-11.2%$71.3M-11.0%$72.8M-16.4%$72.8M-18.3%$79.2M-15.3%$80.1M-22.2%$87.1M-3.6%
Current Liabilities$34.9M+11.7%$30.7M-14.9%$30.2M-14.2%$33.0M-10.7%$31.2M-14.2%$36.1M-10.1%$35.1M-27.0%$36.9M-4.6%
Non-Current Liabilities$37.8M-8.9%$39.6M-8.1%$41.1M-8.5%$39.8M-20.5%$41.6M-21.2%$43.1M-19.2%$45.0M-17.9%$50.1M-2.8%
Total Equity$15.3M-31.0%$20.1M-6.2%$20.5M-5.4%$19.9M-5.6%$22.2M+7.9%$21.4M+7.3%$21.7M+9.2%$21.0M+2.7%
Retained Earnings$808.2M-0.7%$813.2M-0.1%$813.8M-0.1%$811.6M-0.7%$813.9M-0.4%$814.2M-3.6%$814.6M-3.6%$817.1M-3.5%

Not reported in any period shown, so not listed: Inventory, Long-Term Debt.

HHS Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HHS quarterly cash flow statement
MetricQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-Q
Operating Cash Flow-$2.1Mn/m-$575Kn/m$737K-81.8%$3.2Mn/m-$4.8M-401.6%-$818Kn/m$4.0M-7.4%-$2.9M-293.6%
Depreciation & Amortization$1.1M+5.4%$1.1M+1.8%$1.1M-11.9%$1.2M+17.2%$1.1M+4.2%$1.1M+1.6%$1.3M+7.8%$1.0M+9.1%
Stock-Based Compensation$200K0.0%$218Kn/mN/A$200K-50.0%$200K-71.4%-$49K-108.9%N/A$400K+100.0%
Capital Expenditures-$41K-81.6%$347K+230.5%$1.4M+127.0%$1.0M-47.4%$223K-67.3%$105K-80.0%$627K-52.9%$1.9M+753.1%
Free Cash Flow-$2.1Mn/m-$922Kn/m-$686K-120.1%$2.2Mn/m-$5.1M-647.8%-$923Kn/m$3.4M+12.6%-$4.9M-474.1%
Investing Cash Flow$41Kn/m-$347Kn/m-$1.4Mn/m-$1.0Mn/m-$225Kn/m-$103Kn/m-$626Kn/m-$1.9Mn/m
Financing Cash Flow$2.9M+275.7%-$50Kn/m-$41Kn/m-$155Kn/m$778Kn/m-$68Kn/m-$94Kn/m-$163Kn/m
Share BuybacksN/AN/AN/AN/AN/AN/A$0n/m$0-100.0%

Not reported in any period shown, so not listed: Dividends Paid.

HHS Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HHS quarterly financial ratios
MetricQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-Q
Operating Margin-11.8%-11.9pp-2.1%-2.0pp-0.3%+3.0pp1.3%-2.7pp0.1%-3.0pp-0.1%-0.9pp-3.3%+1.3pp4.0%-2.2pp
Net Margin-13.2%-12.3pp-1.7%-0.7pp5.5%+10.7pp-5.8%-6.1pp-0.9%+60.9pp-0.9%-0.6pp-5.2%-1.2pp0.3%-1.0pp
Return on Equity-32.6%-31.1pp-3.1%-1.3pp10.7%+22.0pp-11.5%-12.2pp-1.5%+133.6pp-1.8%-1.0pp-11.2%-1.3pp0.7%-2.3pp
Return on Assets-5.7%-5.3pp-0.7%-0.3pp2.4%+4.8pp-2.5%-2.6pp-0.4%+25.0pp-0.4%-0.2pp-2.4%-0.8pp0.1%-0.4pp
Current Ratio1.30-0.3x1.490.0x1.540.0x1.480.0x1.60+0.1x1.490.0x1.53+0.2x1.46-0.1x
Liabilities-to-Equity4.74+1.5x3.50-0.2x3.47-0.2x3.66-0.5x3.27-1.1x3.70-1.0x3.69-1.5x4.14-0.3x
Asset Turnover0.430.0x0.410.0x0.430.0x0.430.0x0.410.0x0.410.0x0.46+0.1x0.440.0x
FCF Margin-5.6%+7.6pp-2.5%-0.2pp-1.7%-9.0pp5.5%+15.7pp-13.1%-15.2pp-2.2%+11.5pp7.2%+1.1pp-10.2%-13.0pp

Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Harte-Hanks, Inc. HHS FY2025 $159.6M -$811K -0.5% $29.2M 46/100
Star Equity Holdings, Inc. STRR FY2025 $172.2M -$5.9M -3.4% $35.8M 41/100
Planet Green Holdings Corp. PLAG FY2025 $3.0M -$27.0M N/A $5.9M 30/100
Air T Inc AIRT FY2026 $327.1M $78.0M 23.8% $69.9M 28/100
NN Inc NNBR FY2025 $422.2M -$34.0M -8.1% $309.4M 28/100
Mammoth Energy Services, Inc. TUSK FY2025 $44.3M $4.6M 10.4% $128.5M 43/100

Frequently Asked Questions

What is Harte-Hanks, Inc.'s annual revenue?

Harte-Hanks, Inc. (HHS) reported $159.6M in total revenue for fiscal year 2025. This represents a -13.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Harte-Hanks, Inc.'s revenue growing?

Harte-Hanks, Inc. (HHS) revenue declined by 13.9% year-over-year, from $185.2M to $159.6M in fiscal year 2025.

Is Harte-Hanks, Inc. profitable?

No, Harte-Hanks, Inc. (HHS) reported a net loss of $5.7M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net loss of $811K, with a net profit margin of -0.5%.

Harte-Hanks, Inc. (HHS) reported diluted earnings per share of -$0.11 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Harte-Hanks, Inc. (HHS) had EBITDA of $4.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Harte-Hanks, Inc. (HHS) had an operating margin of 0.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Harte-Hanks, Inc. (HHS) had a net profit margin of -0.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Harte-Hanks, Inc. (HHS) has a return on equity of -4.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Harte-Hanks, Inc. (HHS) recorded an outflow of $4.5M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Harte-Hanks, Inc. (HHS) recorded an outflow of $1.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Harte-Hanks, Inc. (HHS) had $91.8M in total assets as of fiscal year 2025, including both current and long-term assets.

Harte-Hanks, Inc. (HHS) invested $2.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Harte-Hanks, Inc. (HHS) had 7M shares outstanding as of fiscal year 2025.

Harte-Hanks, Inc. (HHS) had a current ratio of 1.54 as of fiscal year 2025, which is generally considered healthy.

Harte-Hanks, Inc. (HHS) had a liabilities-to-equity ratio of 3.47 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Harte-Hanks, Inc. (HHS) had a return on assets of -0.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Harte-Hanks, Inc. (HHS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $29.2M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Harte-Hanks, Inc. (HHS) trades at 0.2x sales, its market capitalization divided by $154.6M revenue, trailing 12 months to June 30, 2026. The market capitalization is $29.2M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Harte-Hanks, Inc. (HHS) held $5.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $1.7M over that year. Dividing the one by the other, the reported balance equals about 39 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Harte-Hanks, Inc. (HHS) has an Altman Z-Score of 14.62, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Harte-Hanks, Inc. (HHS) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Harte-Hanks, Inc. (HHS) reported a net loss of $811K while operations used $1.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Harte-Hanks, Inc. (HHS) has an interest coverage ratio of 1.56x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Harte-Hanks, Inc. (HHS) scores 46 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For Harte-Hanks, Inc. it averages the 4 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top